Search

Your search keyword '"Fingerle-Rowson, Guenter"' showing total 163 results
Start Over Author "Fingerle-Rowson, Guenter"
163 results on '"Fingerle-Rowson, Guenter"'

1. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Author

Salles, Gilles, Duell, Johannes, González Barca, Eva, Tournilhac, Olivier, Jurczak, Wojciech, Liberati, Anna Marina, Nagy, Zsolt, Obr, Aleš, Gaidano, Gianluca, André, Marc, Kalakonda, Nagesh, Dreyling, Martin, Weirather, Johannes, Dirnberger-Hertweck, Maren, Ambarkhane, Sumeet, Fingerle-Rowson, Günter, and Maddocks, Kami

Published
2020
Full Text
View/download PDF

2. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Author

Klanova, Magdalena, Sehn, Laurie H., Bence-Bruckler, Isabelle, Cavallo, Federica, Jin, Jie, Martelli, Maurizio, Stewart, Douglas, Vitolo, Umberto, Zaja, Francesco, Zhang, Qingyuan, Mattiello, Federico, Sellam, Gila, Punnoose, Elizabeth A., Szafer-Glusman, Edith, Bolen, Christopher R., Oestergaard, Mikkel Z., Fingerle-Rowson, Guenter R., Nielsen, Tina, and Trneny, Marek

Published
2019
Full Text
View/download PDF

4. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Author

Hertzberg, Mark, Grigg, Andrew, Cannell, Paul, Quach, Hang, Opat, Stephen, Tam, Constantine, Marlton, Paula, Janssens, Ann, Offner, Fritz, Van eygen, Koen, Sangha, Randeep, Mckay, Pam, Wilson, Jonathan, Van Der Jagt, Richard, Roitman, Daryl, Trneny, Marek, Mayer, Jiri, Le Du, Katell, Solal-Celigny, Philippe, Cartron, Guillaume, Foussard, Charles, Frickhofen, Norbert, Schmidt, Peter, Graeven, Ullrich, Gaska, Tobias, Schlag, Rudolf, Sökler, Martin, Prange-Krex, Gabriele, Florschütz, Axel, Lindemann, Hans-Walter, Schimmelpfennig, Christoph, Tonndorf, Solveig, Hänel, Mathias, Hess, Georg, Schalk, Enrico, Hütten, Heiko, Doelken, Gottfried, Pfreundschuh, Michael, Keller, Ulrich, Herold, Michael, Forstpointner, Roswitha, Vehling-Kaiser, Ursula, Hoffmann, Martin, Borbenyi, Zita, Udvardy, Miklos, Demeter, Judit, Rambaldi, Alessandro, Morra, Enrica, Massimo, Federico, Majolino, Ignazio, Balzarotti, Monica, Semenzato, Gianpietro, Canales Albendea, Miguel Angel, Peñalver Parraga, Francisco Javier, Soler Campos, Alfonso, Sancho Cia, Juan Manuel, Marquez Navarro, Jose Antonio, Grande Garcia, Carlos, Nilsson-Ehle, Herman, Mccarthy, Helen, Pocock, Chris, Sadullah, Shalal, Malladi, Ram, Radford, John, Kanfer, Ed, Kruger, Anton, Culligan, Dominic, Dyer, Martin, Pettengell, Ruth, Seymour, John, Gribben, John, Al-Ismail, Saad, Al-Refaie, Faris, Blesing, Norbert, Macnamara, Christopher, O'callaghan, Ann, Haynes, Andrew, Follows, George, Johnson, Roderick, Cunningham, David, Bowles, Kristian, Collins, Graham, Gallop-Evans, Eve, Robinson, Stephen, Subash, Chezhian, Bailey, James, Holden, Viran, Neidhart, Jeffrey, De Oliveira, Moacyr, Tezcan, Haluk, Kim, Kevin, Kambhampati, Suman, Lanier, Keith, Mcclean, John, Tobinai, Kensei, Hatake, Kiyohiko, Ogura, Michinori, Uchida, Toshiki, Ando, Kiyoshi, Kinoshita, Tomohiro, Höhler, Thomas, Stauder, Heribert, Kirsch, Andreas, Koenigsmann, Michael, Kremers, Stephan, Illmer, Thomas, Witzens-Harig, Mathias, La Roseé, Paul, Dürig, Jan, Kneba, Michael, Hensel, Manfred, Fuxius, Stefan, Bergmann, Lothar, Hübel, Kai, Buske, Christian, Marks, Reinhard, Wulf, Gerald, Lerchenmueller, Christian, Schmits, Rudolf, Reinwald, Mark, Lengfelder, Eva, Scott, Fiona, Chou, Takaaki, Taniwaki, Masafumi, Yoshida, Isao, Ishizawa, Kenichi, Uike, Naokuni, Uoshima, Nobuhiko, Kamitsuji, Yuri, Iida, Shinsuke, Ohmine, Ken, Nosaka, Kisato, Ide, Kazuhiko, Ishikawa, Takayuki, Desjardins, Pierre, Finn, Nicholas, Zhu, Jun, Li, Wei, Yu, Li, Ren, Hanyun, Shi, Yuan Kai, Wu, Gang, Hong, Xiaonan, Zhang, Qingyuan, Feng, Jifeng, Zhan, Rong, Lin, Tongyu, Leppa, Sirpa, Costello, Regis, Tempescul, Adrian, Sanhes, Laurence, Tournilhac, Olivier, Kirchen, Heinz, Hebart, Holger, Weide, Rudolf, Jentsch-Ullrich, Kathleen, Avivi, Irit, Nagler, Arnon, Gurion, Ronit, Shpilberg, Ofer, Leoni, Pietro, Baldini, Luca, Samoylova, Olga, Myasnikov, Alexandr, Tan, Tran-Der, Chang, Hung, Kumagai, Kyoya, Tsukamoto, Norifumi, Tsukasaki, Kunihiro, Beatty, Patrick, Usui, Noriko, Izutsu, Koji, Murayama, Tohru, Ichinohe, Tatsuo, Kubo, Kohmei, Ishida, Fumihiro, Beck, J. Thaddeus, Griesinger, Frank, Osmanov, Dzhelil, Dakhil, Shaker, Clavert, Aline, Maruyama, Dai, Terui, Yasuhito, Yamamoto, Kazuhito, Eigendorff, Ekkehard, Kobayashi, Tsutomu, Ichikawa, Satoshi, Choi, Ilseung, Wada, Katsuya, Kikukawa, Yoshitaka, Matsuoka, Masao, Yoshino, Takayuki, Minami, Yosuke, Trotman, Judith, Barrington, Sally F, Belada, David, Meignan, Michel, MacEwan, Robert, Owen, Carolyn, Ptáčník, Václav, Rosta, András, Fingerle-Rowson, Günter R, Zhu, Jiawen, Nielsen, Tina, Sahin, Deniz, Hiddemann, Wolfgang, Marcus, Robert E, and Davies, Andrew

Published
2018
Full Text
View/download PDF

8. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia

Author

Jebaraj, Billy Michael Chelliah, Tausch, Eugen, Landau, Dan A., Bahlo, Jasmin, Robrecht, Sandra, Taylor-Weiner, Amaro N., Bloehdorn, Johannes, Scheffold, Annika, Mertens, Daniel, Böttcher, Sebastian, Kneba, Michael, Jäger, Ulrich, Zenz, Thorsten, Wenger, Michael K., Fingerle-Rowson, Guenter, Wendtner, Clemens, Fink, Anna-Maria, Wu, Catherine J., Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael, Döhner, Hartmut, and Stilgenbauer, Stephan

Published
2019
Full Text
View/download PDF

9. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

Author

Sehn, Laurie H, Chua, Neil, Mayer, Jiri, Dueck, Gregg, Trněný, Marek, Bouabdallah, Kamal, Fowler, Nathan, Delwail, Vincent, Press, Oliver, Salles, Gilles, Gribben, John, Lennard, Anne, Lugtenburg, Pieternella J, Dimier, Natalie, Wassner-Fritsch, Elisabeth, Fingerle-Rowson, Günter, and Cheson, Bruce D

Published
2016
Full Text
View/download PDF

11. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Author

Stilgenbauer, Stephan, Schnaiter, Andrea, Paschka, Peter, Zenz, Thorsten, Rossi, Marianna, Döhner, Konstanze, Bühler, Andreas, Böttcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Winkler, Dirk, Tausch, Eugen, Hoth, Patrick, Edelmann, Jennifer, Mertens, Daniel, Bullinger, Lars, Bergmann, Manuela, Kless, Sabrina, Mack, Silja, Jäger, Ulrich, Patten, Nancy, Wu, Lin, Wenger, Michael K., Fingerle-Rowson, Günter, Lichter, Peter, Cazzola, Mario, Wendtner, Clemens M., Fink, Anna M., Fischer, Kirsten, Busch, Raymonde, Hallek, Michael, and Döhner, Hartmut

Published
2014
Full Text
View/download PDF

12. Tub-010, a Novel Antibody-Drug-Conjugate with Reduced Nonspecific Toxicity Profile Based on Tub-Tag Technology Widens the Therapeutic Window for the Treatment of CD30+ Malignancies

Author

Gerlach, Marcus, primary, Schmitt, Saskia, additional, Cyprys, Philipp, additional, Kasper, Marc-André, additional, Mai, Isabelle, additional, Vermeer, Maarten H., additional, Horwitz, Steven M., additional, Fingerle-Rowson, Guenter R, additional, Vogl, Annette, additional, Schumacher, Dominik, additional, and Helma-Smets, Jonas, additional

Published
2022
Full Text
View/download PDF

14. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor

Author

Reinart, Nina, Nguyen, Phuong-Hien, Boucas, Jorge, Rosen, Natascha, Kvasnicka, Hans-Michael, Heukamp, Lukas, Rudolph, Cornelia, Ristovska, Vangica, Velmans, Tanja, Mueller, Carolin, Reiners, Katrin S., von Strandmann, Elke Pogge, Krause, Günter, Montesinos-Rongen, Manuel, Schlegelberger, Brigitte, Herling, Marco, Hallek, Michael, and Fingerle-Rowson, Günter

Published
2013
Full Text
View/download PDF

15. Intravesical therapy with the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab is well tolerated and shows encouraging preliminary efficacy in patients with high-risk NMIBC (CATUNIBLA phase I trial).

Author

Albert, Felix, primary, Antoniewicz, Aleksander, additional, Grantzow, Tobias, additional, Fingerle-Rowson, Guenter, additional, Ruf, Peter, additional, Lindhofer, Horst, additional, Kriegmair, Maximilian, additional, and Oberneder, Ralph, additional

Published
2022
Full Text
View/download PDF

19. MIF but not MIF-2 recruits inflammatory macrophages in an experimental polymicrobial sepsis model

Author

Tilstam, Pathricia Veronica, Schulte, Wibke, Holowka, Thomas, Kim, Bong-Sung, Nouws, Jessica, Sauler, Maor, Piecychna, Marta, Pantouris, Georgios, Lolis, Elias, Leng, Lin, Bernhagen, Juergen, Fingerle-Rowson, Guenter, Bucala, Richard, Tilstam, Pathricia Veronica, Schulte, Wibke, Holowka, Thomas, Kim, Bong-Sung, Nouws, Jessica, Sauler, Maor, Piecychna, Marta, Pantouris, Georgios, Lolis, Elias, Leng, Lin, Bernhagen, Juergen, Fingerle-Rowson, Guenter, and Bucala, Richard

Abstract

Excessive inflammation drives the progression from sepsis to septic shock. Macrophage migration inhibitory factor (MIF) is of interest because MIF promoter polymorphisms predict mortality in different infections, and anti-MIF antibody improves survival in experimental models when administered 8 hours after infectious insult. The recent description of a second MIF superfamily member, D-dopachrometautomerase (D-DT/MIF-2), prompted closer investigation of MIF-dependent responses. We subjected Mif(-/-) and Mif-2(-/-) mice to polymicrobial sepsis and observed a survival benefit with Mif but not Mif-2 deficiency. Survival was associated with reduced numbers of small peritoneal macrophages (SPMs) that, in contrast to large peritoneal macrophages (LPMs), were recruited into the peritoneal cavity. LPMs produced higher quantities of MIF than SPMs, but SPMs expressed higher levels of inflammatory cytokines and the MIF receptors CD74 and CXCR2. Adoptive transfer of WT SPMs into Mif(-/-) hosts reduced the protective effect of Mif deficiency in polymicrobial sepsis. Notably, MIF-2 lacks the pseudo-(E) LR motif present in MIF that mediates CXCR2 engagement and SPM migration, supporting a specific role for MIF in the recruitment and accumulation of inflammatory SPMs.

Published
2021

21. Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Author

Langerak, Anton W., Ritgen, Matthias, Goede, Valentin, Robrecht, Sandra, Bahlo, Jasmin, Fischer, Kirsten, Steurer, Michael, Trněný, Marek, Mulligan, Stephen P., Mey, Ulrich J.M., Trunzer, Kerstin, Fingerle-Rowson, Günter, Humphrey, Kathryn, Stilgenbauer, Stephan, Böttcher, Sebastian, Brüggemann, Monika, Hallek, Michael, Kneba, Michael, and van Dongen, Jacques J.M.

Published
2019
Full Text
View/download PDF

22. CD74 is dispensable for development of chronic lymphocytic leukemia inE mu-TCL1 transgenic mice

Author

Barthel, Romy, Fedorchenko, Oleg, Velmans, Tanja, Rosen, Natascha, Reinart, Nina, Florin, Alexandra, Herling, Marco, Hallek, Michael, Fingerle-Rowson, Guenter, Barthel, Romy, Fedorchenko, Oleg, Velmans, Tanja, Rosen, Natascha, Reinart, Nina, Florin, Alexandra, Herling, Marco, Hallek, Michael, and Fingerle-Rowson, Guenter

Abstract

CD74 is a surface protein expressed on immune cells, which acts as receptor for the chemokine macrophage migration inhibitory factor (MIF). Signalingviathe MIF/CD74-axis has been reported to be important for the pathogenesis of chronic lymphocytic leukemia (CLL). We wanted to clarify the role of CD74 in MIF-induced signaling/leukemic development. In E mu-TCL1 transgenic mice, occurrence of the leukemic phenotype was associated with increased surface CD74 expression. E mu-TCL1(+/+)Cd74(-/-)mice showed similar kinetics and clinical features of CLL development as E mu-TCL1(+/+)mice. MIF stimulation of leukemic splenocytes led to AKT activation in a CD74-dependent manner. AKT activation was reduced in Cd74-deficient splenocytes in the presence of the oncogenic TCL1-transgene. Tumor cell apoptosis/proliferation were unaffected in E mu-TCL1(+/+)Cd74(-/-)mice. Our data suggest that the need for active CD74 signaling is overcome in the leukemic context of TCL1-driven CLL, and that CD74 may have a dispensable role for CLL pathogenesis in this model.

Published
2020

23. MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial

Author

Pott, Christiane, primary, Sehn, Laurie H., additional, Belada, David, additional, Gribben, John, additional, Hoster, Eva, additional, Kahl, Brad, additional, Kehden, Britta, additional, Nicolas-Virelizier, Emmanuelle, additional, Spielewoy, Nathalie, additional, Fingerle-Rowson, Guenter, additional, Harbron, Chris, additional, Mundt, Kirsten, additional, Wassner-Fritsch, Elisabeth, additional, and Cheson, Bruce D., additional

Published
2019
Full Text
View/download PDF

24. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy

Author

Klanova, Magdalena, Oestergaard, Mikkel Z., Trneny, Marek, Hiddemann, Wolfgang, Marcus, Robert, Sehn, Laurie H., Vitolo, Umberto, Bazeos, Alexandra, Goede, Valentin, Zeuner, Harald, Knapp, Andrea, Sahin, Deniz, Spielewoy, Nathalie, Bolen, Christopher R., Cardona, Andres, Klein, Christian, Venstrom, Jeffrey M., Nielsen, Tina, Fingerle-Rowson, Guenter, Klanova, Magdalena, Oestergaard, Mikkel Z., Trneny, Marek, Hiddemann, Wolfgang, Marcus, Robert, Sehn, Laurie H., Vitolo, Umberto, Bazeos, Alexandra, Goede, Valentin, Zeuner, Harald, Knapp, Andrea, Sahin, Deniz, Spielewoy, Nathalie, Bolen, Christopher R., Cardona, Andres, Klein, Christian, Venstrom, Jeffrey M., Nielsen, Tina, and Fingerle-Rowson, Guenter

Abstract

Purpose: Natural killer (NK) cells are key effector cells for anti-CD20 monoclonal antibodies (mAb), such as obinutuzumab and rituximab. We assessed whether low pretreatment NK-cell count (NKCC) in peripheral blood or tumor tissue was associated with worse outcome in patients receiving antibodybased therapy. Patients and Methods: Baseline peripheral blood NKCC was assessed by flow cytometry (CD3(-) CD56(+) and/or CD16(+) cells) in 1,064 of 1,202 patients with follicular lymphoma treated with obinutuzumab or rituximab plus chemotherapy in the phase III GALLIUM trial (NCT01332968) and 1,287 of 1,418 patients with diffuse large B-cell lymphoma (DLBCL) treated with obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP or R-CHOP) in the phase III GOYA trial (NCT01287741). The prognostic value of tumor NK-cell gene expression, as assessed by whole-transcriptome gene expression using TruSeq RNA sequencing, was also analyzed. The association of baseline variables, such as treatment arm, was evaluated using multivariate Cox regression models using a stepwise approach. Results: In this exploratory analysis, low baseline peripheral blood NKCC was associated with shorter progression-free survival (PFS) in both follicular lymphoma [hazard ratio (HR), 1.48; 95% confidence interval (CI), 1.02-2.14; P = 0.04] and DLBCL (HR, 1.36; 95% CI, 1.01-1.83; P = 0.04), and overall survival in follicular lymphoma (HR, 2.20; 95% CI, 1.26-3.86; P = 0.0058). Low tumor NK-cell gene expression was associated with shorter PFS in G-CHOP-treated patients with DLBCL (HR, 1.95; 95% CI, 1.22-3.15; P < 0.01). Conclusions: These findings indicate that the number of NK cells in peripheral blood may affect the outcome of patients with B-cell non-Hodgkin lymphoma receiving anti-CD20 based immunochemotherapy.

Published
2019

25. Macrophage migration inhibitory factor promotes renal injury induced by ischemic reperfusion

Author

Li, Jin H., Tang, Ying, Lv, Jun, Wang, Xiao H., Yang, Hui, Tang, Patrick M. K., Huang, Xiao R., He, Zhi J., Zhou, Zi J., Huang, Qiu Y., Klug, Joerg, Meinhardt, Andreas, Fingerle-Rowson, Guenter, Xu, An P., Zheng, Zhi H., Lan, Hui Yao, Li, Jin H., Tang, Ying, Lv, Jun, Wang, Xiao H., Yang, Hui, Tang, Patrick M. K., Huang, Xiao R., He, Zhi J., Zhou, Zi J., Huang, Qiu Y., Klug, Joerg, Meinhardt, Andreas, Fingerle-Rowson, Guenter, Xu, An P., Zheng, Zhi H., and Lan, Hui Yao

Abstract

Macrophage migration inhibitory factor (MIF) is pleiotropic cytokine that has multiple effects in many inflammatory and immune diseases. This study reveals a potential role of MIF in acute kidney injury (AKI) in patients and in kidney ischemic reperfusion injury (IRI) mouse model in MIF wild-type (WT) and MIF knockout (KO) mice. Clinically, plasma and urinary MIF levels were largely elevated at the onset of AKI, declined to normal levels when AKI was resolved and correlated tightly with serum creatinine independent of disease causes. Experimentally, MIF levels in plasma and urine were rapidly elevated after IRI-AKI and associated with the elevation of serum creatinine and the severity of tubular necrosis, which were suppressed in MIF KO mice. It was possible that MIF may mediate AKI via CD74/TLR4-NF-kappa B signalling as mice lacking MIF were protected from AKI by largely suppressing CD74/TLR-4-NF-kappa B associated renal inflammation, including the expression of MCP-1, TNF-alpha, IL-1 beta, IL-6, iNOS, CXCL15(IL-8 in human) and infiltration of macrophages, neutrophil, and T cells. In conclusion, our study suggests that MIF may be pathogenic in AKI and levels of plasma and urinary MIF may correlate with the progression and regression of AKI.

Published
2019

26. Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)

Author

Al-Sawaf, Othman, Bazeos, Alexandra, Robrecht, Sandra, Bahlo, Jasmin, Gower, Craig, Fink, Anna-Maria, Tresckow, Julia, Cramer, Paula, Langerbeins, Petra, Kutsch, Nadine, Humphrey, Kathryn, Fingerle-Rowson, Guenter, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael, Goede, Valentin, Al-Sawaf, Othman, Bazeos, Alexandra, Robrecht, Sandra, Bahlo, Jasmin, Gower, Craig, Fink, Anna-Maria, Tresckow, Julia, Cramer, Paula, Langerbeins, Petra, Kutsch, Nadine, Humphrey, Kathryn, Fingerle-Rowson, Guenter, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael, and Goede, Valentin

Abstract

In CLL, progressive disease (PD) following remission after first line treatment can present with varying phenotypes. We hypothesized that the mode of PD correlates with clinical outcomes. Data from three phase III trials of the German CLL Study Group (GCLLSG) (CLL8, CLL10, CLL11) including a total of 2159 patients receiving first line (immuno)-chemotherapy (FCR, FC, CLB, CLB-R, CLB-Ob) were analyzed. Patients were categorized as ALC if PD was due to increasing absolute lymphocyte count, or as Ly if due to lymphadenopathy. A group of 241 patients progressed with ALC, and 727 progressed with Ly, including 329 who progressed on both modalities. In fit patients, median TTNT after PD in the Ly group was 12.3 months vs 17.0 months in the ALC group (HR 1.299 [1.036-1.628]; P = .024). Median OS after PD was 45.1 months in the Ly group and 42.4 months in the ALC group (HR=1.023 [0.753-1.389]; P = .885). For unfit patients, median TTNT in the Ly group was 11.7 months vs 21.4 months in the ALC group (HR 1.357 [1.051-1.753]; P = .019). Median OS was 42.8 months in the Ly group and not reached in the ALC group (HR 1.851 [1.280-2.677]; P = .001). Patients in the Ly group more frequently showed impairment of quality of life (QoL). This analysis demonstrates that patients with progressive lymphadenopathy have a significantly shorter TTNT, OS and less favorable QoL. Our findings might help physicians to better estimate the clinical course of a progressing CLL patient.

Published
2019

28. FcmR Shapes BCR Signaling in IgM-Positive Leukemia

Author

Guerreiro, Alexandra da Palma, Dorweiler, Cornelia, Halmer, Ismini, Merkel, Olaf, Hartmann, Elena Maria, Berg, Valeska, Reinart, Nina, Fingerle-Rowson, Guenter, Knittel, Gero, Pallasch, Christian, Rosenwald, Andreas, Reinhardt, Christian, Wendtner, Clemens-Martin, Hallek, Michael, Frenzel, Lukas P., Guerreiro, Alexandra da Palma, Dorweiler, Cornelia, Halmer, Ismini, Merkel, Olaf, Hartmann, Elena Maria, Berg, Valeska, Reinart, Nina, Fingerle-Rowson, Guenter, Knittel, Gero, Pallasch, Christian, Rosenwald, Andreas, Reinhardt, Christian, Wendtner, Clemens-Martin, Hallek, Michael, and Frenzel, Lukas P.

Published
2018

29. A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase

Author

Belada, David, Nowakowski, Grzegorz S., Bergua Burgues, Juan Miguel, André, Marc, Kopeckova, Katerina, Stevens, Don A., Trněný, Marek, Pérez Persona, Ernesto, Pichler, Petra, Klöpfer, Pia, Brackertz, Bettina, Lohrmann, Emanuel, Lahiry, Anirban, Shah, Neha, Fingerle-Rowson, Günter, Brugger, Wolfram, and Burke, John M.

Published
2020
Full Text
View/download PDF

30. ABCL-135: RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Author

Rodgers, Thomas, Luigi Zinzani, Pier, Marino, Dario, Frezzato, Maurizio, Maria Barbui, Anna, Castellino, Claudia, Meli, Erika, Conconi, Annarita, Cascavilla, Nicola, Cavallo, Federica, H Fowler, Nathan, Feinberg, Bruce, Tillmanns, Sascha, Parche, Stephan, Fingerle-Rowson, Günter, Winderlich, Mark, Ambarkhane, Sumeet, Salles, Gilles, and Nowakowski, Grzegorz

Published
2020
Full Text
View/download PDF

32. Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen-presenting cells in skin

Author

Brocks, Tania, Fedorchenko, Oleg, Schliermann, Nicola, Stein, Astrid, Moll, Ute M., Seegobin, Seth, Dewor, Manfred, Hallek, Michael, Marquardt, Yvonne, Fietkau, Katharina, Heise, Ruth, Huth, Sebastian, Pfister, Herbert, Bernhagen, Juergen, Bucala, Richard, Baron, Jens M., Fingerle-Rowson, Guenter, Brocks, Tania, Fedorchenko, Oleg, Schliermann, Nicola, Stein, Astrid, Moll, Ute M., Seegobin, Seth, Dewor, Manfred, Hallek, Michael, Marquardt, Yvonne, Fietkau, Katharina, Heise, Ruth, Huth, Sebastian, Pfister, Herbert, Bernhagen, Juergen, Bucala, Richard, Baron, Jens M., and Fingerle-Rowson, Guenter

Abstract

The response of the skin to harmful environmental agents is shaped decisively by the status of the immune system. Keratinocytes constitutively express and secrete the chemokine-like mediator, macrophage migration inhibitory factor (MIF), more strongly than dermal fibroblasts, thereby creating a MIF gradient in skin. By using global and epidermis-restricted Mif-knockout (Mif(-1-) and K14-Cre(+ltg) ;Mif(fllft)) mice, we found that MIF both recruits and maintains antigen-presenting cells in the dermis/epidermis. The reduced presence of antigen-presenting cells in the absence of MIF was associated with accelerated and increased formation of nonmelanoma skin tumors during chemical carcinogenesis. Our results demonstrate that MIF is essential for maintaining innate immunity in skin. Loss of keratinocyte-derived MIF leads to a loss of control of epithelial skin tumor formation in chemical skin carcinogenesis, which highlights an unexpected tumor-suppressive activity of MIF in murine skin.- Brocks, T., Fedorchenko, O., Schliermann, N., Stein, A., Moll, U. M., Seegobin, S., Dewor, M., Hallek, M., Marquardt, Y., Fietkau, K., Heise, R., Huth, S., Pfister, H., Bernhagen, J., Bucala, R., Baron, J. M., Fingerle-Rowson, G. Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen-presenting cells in skin.

Published
2017

33. A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

Author

Burke, John M, André, Marc, Cheson, Bruce D., Duell, Johannes, Nowakowski, Grzegorz, Rosenwald, Andreas, Salles, Gilles A., Sharman, Jeff P., Staber, Philipp Bernhard, Trněný, Marek, Westin, Jason R., Brugger, Wolfram, Fingerle-Rowson, Günter, Klanova, Magdalena, Würth, Guido, and Truemper, Lorenz

Published
2019
Full Text
View/download PDF

34. Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia

Author

Mueller, Dirk, Fischer, Kirsten, Kaiser, Peter, Eichhorst, Barbara, Walshe, Ronald, Reiser, Marcel, Kellermann, Lenka, Borsi, Lisa, Civello, Daniele, Mensch, Alexander, Bahlo, Jasmin, Hallek, Michael, Stock, Stephanie, Fingerle-Rowson, Guenter, Mueller, Dirk, Fischer, Kirsten, Kaiser, Peter, Eichhorst, Barbara, Walshe, Ronald, Reiser, Marcel, Kellermann, Lenka, Borsi, Lisa, Civello, Daniele, Mensch, Alexander, Bahlo, Jasmin, Hallek, Michael, Stock, Stephanie, and Fingerle-Rowson, Guenter

Abstract

The cost-effectiveness of rituximab in combination with fludarabine/cyclophosphamide (R-FC) for the first line treatment of chronic lymphocytic leukemia (CLL) was evaluated. Based on long-term clinical data (follow-up of 5.9 years) from the CLL8-trial, a Markov-model with three health states (Free from disease progression, Progressive disease, Death) was used to evaluate the cost per quality-adjusted life-year (QALY) and cost per life years gained (LYG) of R-FC from the perspective of the German statutory health insurance (SHI). The addition of rituximab to FC chemotherapy results in a gain of 1.1 quality-adjusted life-years. The incremental cost-effectiveness ratio (ICER) of R-FC compared with FC was Euro17 979 per QALY (Euro15 773 per LYG). Results were robust in deterministic and probabilistic sensitivity analyses. From the German SHI perspective, rituximab in combination with FC chemotherapy represents good value for first-line treatment of patients with CLL and compares favorably with chemotherapy alone.

Published
2016

35. Loss of TOSO Promotes Richter's Transformation of TCL1A Driven CLL

Author

Guerreiro, Alexandra da Palma, Dorweiler, Cornelia, Kintzele, Laurent, Baatout, Dunja, Huelsemann, Malte, Berg, Valeska, Merkel, Olaf, Reinart, Nina, Fingerle-Rowson, Guenter, Knittel, Gero, Pallasch, Christian, Reinhardt, Hans Christian, Wendtner, Clemens Martin, Hallek, Michael, Frenzel, Lukas P., Guerreiro, Alexandra da Palma, Dorweiler, Cornelia, Kintzele, Laurent, Baatout, Dunja, Huelsemann, Malte, Berg, Valeska, Merkel, Olaf, Reinart, Nina, Fingerle-Rowson, Guenter, Knittel, Gero, Pallasch, Christian, Reinhardt, Hans Christian, Wendtner, Clemens Martin, Hallek, Michael, and Frenzel, Lukas P.

Published
2016

36. Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11 Study Population

Author

Goede, Valentin, Bahlo, Jasmin, Kutsch, Nadine, Fischer, Kirsten, Fink, Anna Maria, Fingerle-Rowson, Guenter, Stilgenbauer, Stephan, Bergmann, Manuela A., Eichhorst, Barbara F., Hallek, Michael, Goede, Valentin, Bahlo, Jasmin, Kutsch, Nadine, Fischer, Kirsten, Fink, Anna Maria, Fingerle-Rowson, Guenter, Stilgenbauer, Stephan, Bergmann, Manuela A., Eichhorst, Barbara F., and Hallek, Michael

Published
2016

37. Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11 Study Population

Author

Goede, Valentin, primary, Bahlo, Jasmin, additional, Kutsch, Nadine, additional, Fischer, Kirsten, additional, Fink, Anna Maria, additional, Fingerle-Rowson, Guenter, additional, Stilgenbauer, Stephan, additional, Bergmann, Manuela A., additional, Eichhorst, Barbara F., additional, and Hallek, Michael, additional

Published
2016
Full Text
View/download PDF

38. Loss of TOSO Promotes Richter's Transformation of TCL1A Driven CLL

Author

da Palma Guerreiro, Alexandra, primary, Dorweiler, Cornelia, additional, Kintzelé, Laurent, additional, Baatout, Dunja, additional, Huelsemann, Malte, additional, Berg, Valeska, additional, Merkel, Olaf, additional, Reinart, Nina, additional, Fingerle-Rowson, Guenter, additional, Knittel, Gero, additional, Pallasch, Christian, additional, Reinhardt, Hans Christian, additional, Wendtner, Clemens Martin, additional, Hallek, Michael, additional, and Frenzel, Lukas P., additional

Published
2016
Full Text
View/download PDF

39. Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen‐presenting cells in skin

Author

Brocks, Tania, primary, Fedorchenko, Oleg, additional, Schliermann, Nicola, additional, Stein, Astrid, additional, Moll, Ute M., additional, Seegobin, Seth, additional, Dewor, Manfred, additional, Hallek, Michael, additional, Marquardt, Yvonne, additional, Fietkau, Katharina, additional, Heise, Ruth, additional, Huth, Sebastian, additional, Pfister, Herbert, additional, Bernhagen, Juergen, additional, Bucala, Richard, additional, Baron,, Jens M., additional, and Fingerle‐Rowson, Guenter, additional

Published
2016
Full Text
View/download PDF

40. FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study

Author

Kostakoglu, Lale, primary, Goy, Andre, additional, Martinelli, Giovanni, additional, Caballero, Dolores, additional, Crump, Michael, additional, Gaidano, Gianluca, additional, Baetz, Tara, additional, Buckstein, Rena, additional, Fine, Gregg, additional, Fingerle-Rowson, Guenter, additional, Berge, Claude, additional, Sahin, Deniz, additional, Press, Oliver, additional, and Sehn, Laurie, additional

Published
2016
Full Text
View/download PDF

41. FcmR Shapes BCR Signaling in IgM-Positive Leukemia

Author

da Palma Guerreiro, Alexandra, Dorweiler, Cornelia, Halmer, Ismini, Merkel, Olaf, Hartmann, Elena Maria, Berg, Valeska, Reinart, Nina, Fingerle-Rowson, Günter, Knittel, Gero, Pallasch, Christian, Rosenwald, Andreas, Reinhardt, Christian, Wendtner, Clemens-Martin, Hallek, Michael, and Frenzel, Lukas P.

Published
2018
Full Text
View/download PDF

42. Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009

Author

Schmidt, Christian, Fingerle-Rowson, Guenter, Boehme, Angelika, Brendel, Kurt, Fischer, Richard, Gonnermann, Michael, Hoehler, Thomas, Kegel, Thomas, Kellermann, Lenka, Nusch, Arndt, Poenisch, Wolfram, Wendtner, Clemens, Dreyling, Martin, Schmidt, Christian, Fingerle-Rowson, Guenter, Boehme, Angelika, Brendel, Kurt, Fischer, Richard, Gonnermann, Michael, Hoehler, Thomas, Kegel, Thomas, Kellermann, Lenka, Nusch, Arndt, Poenisch, Wolfram, Wendtner, Clemens, and Dreyling, Martin

Abstract

Today's treatment options for indolent lymphoma and chronic lymphocytic leukemia (CLL) range from watch & wait, immunochemotherapy up to allogeneic transplantation. We describe changes in the diagnosis and treatment of indolent lymphoma and CLL in Germany between 2006 and 2009. Two nation-wide surveys in the fourth quarter of 2006 and 2009 included patients with indolent lymphoma and CLL. Data from 576 patients from 46 centers in Q4/2006 were compared with data from 521 patients from 57 centers in Q4/2009. The subpopulation of patients >= 70 years of age and the number of patients with comorbidities increased from 39% to 55% and 47% to 55%, respectively. Both in indolent lymphoma and CLL, Rituximab and R-based immunochemotherapy (50.6% vs. 64.4%) as well as bendamustine (4.8% vs. 24%) were much more frequently applied. In contrast, high dose chemotherapy consolidation was almost abandoned in first line treatment. Supportive care is given more frequently, with exception of erythropoietin and immunoglobulins. Our national survey confirmed that scientific results were rapidly transferred into clinical care of indolent lymphoma.

Published
2015

43. Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Author

Till, Brian G., primary, Park, Steven I., additional, Popplewell, Leslie L., additional, Goy, Andre, additional, Penuel, Elicia, additional, Venstrom, Jeffrey M, additional, Liu, Bo, additional, Fingerle-Rowson, Guenter, additional, Byon, John, additional, Woodard, Paul, additional, and Palomba, M. Lia, additional

Published
2015
Full Text
View/download PDF

44. GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.

Author

Sehn, Laurie Helen, primary, Chua, Neil Sun, additional, Mayer, Jiri, additional, Dueck, Gregory Scott, additional, Trněný, Marek, additional, Bouabdallah, Kamal, additional, Fowler, Nathan Hale, additional, Delwail, Vincent, additional, Press, Oliver W., additional, Salles, Gilles A., additional, Gribben, John G., additional, Lennard, Anne, additional, Lugtenburg, Pieternella J., additional, Franklin, Natalie, additional, Wassner Fritsch, Elisabeth, additional, Fingerle-Rowson, Guenter, additional, and Cheson, Bruce D., additional

Published
2015
Full Text
View/download PDF

45. Influence of Baseline Disease Characteristics and Exposure to Obinutuzumab on Clinical Outcome in Patients with Previously Untreated Advanced Follicular Lymphoma Treated with Obinutuzumab-Based Immunochemotherapy in the GALLIUM Trial

Author

Jamois, Candice, Gibiansky, Ekaterina, Gibiansky, Leonid, Buchheit, Vincent, Baumlin, Pauline, Sahin, Denis, Cartron, Guillaume, Marcus, Robert, Hiddemann, Wolfgang, Seymour, John F, Strefford, Jonathan C, Meneses-Lorente, Georgina, Frey, Nicolas, and Fingerle-Rowson, Günter

Published
2017
Full Text
View/download PDF

49. RPS15 mutations and Treatment Outcome in Chronic Lymphocytic Leukemia - Results from the CLL11 Phase III Trial (Chlorambucil (Clb) with or without the Addition of Rituximab (R) or Obinutuzumab (GA101, G)) of the German CLL Study Group

Author

Estenfelder, Sven, Holland-Letz, Ann-Kathrin, Tausch, Eugen, Robrecht, Sandra, Bahlo, Jasmin, Goede, Valentin, Opatrna, Veronika, Ritgen, Matthias, van Dongen, Jacques JM, Langerak, Anton W, Fingerle-Rowson, Günter, Kneba, Michael, Fischer, Kirsten, Hallek, Michael, Döhner, Hartmut, and Stilgenbauer, Stephan

Published
2017
Full Text
View/download PDF

50. Short Telomeres Are Independent Prognostic Factors Associated with Poor Outcome in Chronic Lymphocytic Leukemia (CLL) Treated with Chlorambucil with or without the Addition of Rituximab or Obinutuzumab: Results from CLL11 Trial of the Gcllsg

Author

Jebaraj, Billy Michael Chelliah, Scheffold, Annika, Robrecht, Sandra, Bahlo, Jasmin, Goede, Valentin, Tausch, Eugen, Estenfelder, Sven, Opatrna, Veronika, Ritgen, Matthias, van Dongen, Jacques JM, Langerak, Anton W, Fingerle-Rowson, Günter, Kneba, Michael, Fischer, Kirsten, Hallek, Michael J., Döhner, Hartmut, and Stilgenbauer, Stephan

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results